854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)

Jérôme Fayette, Lisa Licitra, Kevin J. Harrington, Robert I. Haddad, Lillian L. Siu, Yi‐Chun Liu, Makoto Tahara, J-P. Machiels, Danny Rischin, Tanguy Y. Seiwert, Robert L. Ferris, Ulrich Keilholz, Amanda Psyrri, Bhumsuk Keam, Paolo Bossi, Robert Metcalf, Oscar K. Serrano, Paramjit Kaur, Dario Ruscica, Roger B. Cohen